jasmina simonovic babic - Infectious Diseases

Author Information

Jasmina Simonović-Babić is affiliated with the Clinic for Infectious and Tropical Diseases at the Clinical Centre of Serbia, located in Belgrade, Serbia. Her research primarily focuses on infectious diseases, particularly chronic hepatitis B and C. With a strong clinical background, she contributes significantly to understanding and treating viral infections in resource-limited settings.

Research Contributions

Jasmina Simonović-Babić has made notable contributions to the field of infectious diseases, with a particular emphasis on hepatitis B and C. Her research work spans from evaluating the efficacy and safety of antiviral therapies, such as pegylated-interferon and ombitasvir/paritaprevir/ritonavir, to exploring genetic factors like the UGT1A1*28 and IL-28B genotypes in liver injury outcomes. Her studies also cover broader therapeutic strategies, including micro-elimination of HCV, indicating her comprehensive approach to tackling viral hepatitis.

Aliases

Jasmina Simonović-Babić is also known by the alias Jasmina Simonovic-babic. This alternate spelling is used in some of her publications and citations.

Publication and Citation Metrics

Metric	Value
Total Citation Count	27
h-index	3
Total Paper Count	13

Publications:

Efficacy and safety of pegylated-interferon alpha therapy in patients with chronic hepatitis B in recource-limited settings- Serbian single-center experience

DOI: 10.2298/VSP180727150B

Year: 2020

Micro-elimination of HCV as a possible therapeutic strategy: our experience and a review of literature.

DOI: 10.3855/jidc.11785

Year: 2020

Significance of UGT1A1*28 Genotype in Patients with Advanced Liver Injury Caused By Chronic Hepatitis C

DOI: 10.2478/jomb-2018-0015

Year: 2019

Herpes zoster - is there a need for new treatment recommendations?

DOI: 10.2298/vsp170905021k

Year: 2019

IL-28B genotypes as predictors of long-term outcome in patients with hepatitis C-related severe liver injury.

DOI: 10.3855/JIDC.11351

Year: 2019

Real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir +ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia

DOI: 10.2298/VSP170727186S

Year: 2019

SIGNIFICANCE OF UGT 1 A 1 * 28 GENOTYPE IN PATIENTS WITH ADVANCED LIVER INJURY CAUSED BY CHRONIC HEPATITIS C ZNA

DOI:

Year: 2018

[The efficacy of lamivudine in the treatment of reactivation of chronic hepatitis B virus infection in patients on immunosuppressive therapy].

DOI: 10.2298/SARH1112824P

Year: 2011

SEQUENCE VARIABILITY AT THE INTERNAL RIBOSOME ENTRY SITE OF THE HCV GENOME IN RELATION TO THERAPY OUTCOME

DOI: 10.2298/ABS0902205J

Year: 2009

[The role of interferon in the treatment of acute hepatitis C].

DOI: 10.2298/MPNS0708322S

Year: 2007

What Are Antigen Presenting Cells?

How Does the Immune System Recognize Pathogens?

Can Colonization Lead to Infection?

Are There Any Emerging Technologies in Mosquito Control?

What is the Scope of Infectious Diseases?

How Does Parasite DNA Contribute to Drug Resistance?

How Do Vectors Transmit Diseases?

What precautions are necessary during air travel?

How is Ebola Diagnosed?

What is Artemisinin?

Partnered Content Networks

Relevant Topics